Duska Therapeutics Enrolls First Patient in ATPace Phase II Trial.

BALA CYNWYD, Pa. -- Duska Therapeutics, Inc. (OTC BB:DSKT) announced today that on March 30, the first patient was enrolled in a Phase II clinical trial that the Company is conducting with its lead drug ATPace(TM). Twenty leading medical centers in the US and Canada are planned to participate in this trial. ATPace(TM), which is a liquid formulation of adenosine 5'-trphosphate (ATP), is being developed by Duska as a diagnostic drug aimed at the identification of patients with bradycardic syncope (i.e., fainting due to an abnormally slow heart rate) who may benefit from pacemaker therapy. Three hundred (300) patients with various types of syncope and two hundred fifty (250) control subjects are expected to be enrolled in this study.

"We are pleased to have now begun enrollment of patients in this important multi-center trial, and look forward to enrolling additional patients in the near future as additional centers commence patient enrollment," said Dr. Amir Pelleg, Duska's President and Chief Scientific Officer.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., based in Bala Cynwyd, Pennsylvania, is an emerging biopharmaceutical company that is focusing on the development of diagnostic and therapeutic products related to adenosine 5'-triphosphate (ATP), and ATP related P2 receptors (P2R). Duska currently carries out all of its business operations through its wholly owned subsidiary, Duska Scientific Co. Duska owns or has exclusive license rights to a number of proprietary diagnostic and therapeutic applications, four of which are currently in various stages of development in the fields of syncope (fainting), male infertility, chronic obstructive pulmonary disease (COPD) and cough, and asthma. For more information, visit Duska's website: www.duskascientific.com

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the rate at which Duska may be able to enroll patients in its Phase II trial with ATPace(TM) and its outcome, the early stage of Duska's drug development projects, the need for future clinical trials with Duska's drug candidates, their scope as may be required by regulatory authorities and their outcomes, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, Duska's need for additional capital to fund its ongoing operations including drug development, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies regarding the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.